Prevention Clinical Trials 2023

Prevention Clinical Trials 2023

Prevention research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in prevention clinical trials today.

Trials for Prediabetes Patients

Montreal, Quebec

Behavioral Intervention

Chronic care management 1-6 for High Blood Pressure

Recruiting1 award2 criteria
Montreal, Quebec

CONTEXTE: L'Agence de la santé et des services sociaux de Montréal (ASSS) invited our research team to evaluate the implementation of an integrated and interdisciplinary primary care network for prevention and management of cardiometabolic risks (diabetes and hypertension) (PCR). The intervention is based on the Chronic Care Model and the development of an integrated services network. PCR is to be implemented in 6 territories of "Centre de santé et de services sociaux (CSSS)". A first application for funding was made to Fonds Pfizer-FRSQ-MSSS for an evaluation that has to be completed in the first 24 month after the beginning of the implementation. This application to the PHSI program at CIHR is complementary and will ensure an evaluation of the sustainability of PCR and of long term effects (40 months after the beginning of the implementation) for patients and for their primary care physicians. In each CSSS, PCR plans for : 1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors of "Réseau local de services (RLS)" insuring clinical information transfer required for efficient patient management. OBJECTIVES: 1-evaluate PCR effects according to territory, time and degree of exposure (specifically benefits to registered patients and support to participating primary care physicians); 2- identify the degree of implementation of PCR in each CSSS territory and the related contextual factors; 3- examine the relationship between the effects identified, the degree of implementation of PCR and the related contextual factors; 4- assess the impact of implementing PCR on the strengthening of RLS. METHODS: The proposed evaluation will be done through a mixed design including two complementary strategies. Using a "quasi-experiment/before-after" design, the first strategy is a quantitative approach looking at the program effects and their variation between territories. This analysis will use data from the PCR clinical database (ex.: HbA1c, BP, lifestyle) and from patient questionnaire inquiring about care experience, utilization of services, chronic care follow-up, self-management and quality of life. Around 3000 patients will be enlisted. A primary care physician questionnaire will enquire about PCR effects on their practice. Using primarily a qualitative and a case study approach, each of the 6 territories being one case, the second strategy will identify the degree of implementation of PCR and the explanatory contextual factors. This analysis with use data obtained from semi-structured interviews with program managers. The results of this analysis will be summarized in a monograph for each territory. According to the type of indicator analyzed, objective 3 will be fulfilled using linear models or longitudinal multilevel models supplemented with an interpretive approach using the information from monographs and discussion groups. The impact of implementing PCR on RLS will be assessed through interviews with key informants. RESULTS AND EXPECTED IMPACT: Our study will identify the effectiveness of PCR and contextual factors associated with successful implementation and sustainability of PCR. Detailed contextual information will allow application of our results to other environments that have similar context and to other chronic conditions that could benefit from an integrated services network. KNOWLEDGE TRANSFER: Since decision makers, clinicians and researchers did and will take part in all phases of PRC evaluation (planning, data collection, analysis and interpretation), diffusion of information regarding the program is an integral part of the research process. In addition, results will be presented at local, regional, provincial and national conferences and published in reports and articles widely distributed. More specifically, a regional symposium will be organized to share evaluation results with all CSSS in the region (n=12) and with all our local and regional partners.
Miami, Florida

Behavioral Intervention

Peer-led intervention +1 More for Diabetes

Recruiting1 award5 criteria
Miami, Florida

The prevalence of obesity and diabetes in older adults is increasing. Because older adults are often portrayed as less likely to change long-standing health behaviors, health promotion in this age group has lagged behind others. In fact, little attention has been given to the importance of diabetes prevention in community-dwelling older adults through the implementation of programs that promote healthy nutrition, increase physical activity and improve self-management. The Diabetes Prevention Program (DPP), which demonstrated the benefit of modest weight loss on the reduction of diabetes risk (58% overall reduction with a 71% reduction in the older population), has yet to be translated into widespread public health practice. The overall objective of this protocol is to implement evidence-informed, innovative interventions to increase adoption of findings from comparative effectiveness research (CER) for diabetes management and prevention in South Florida older veterans. Specifically, the proposed study will test the hypothesis that Peer-led Care alone (PC), or activated by technology (TechnAlert-Peer or TAP), is superior to traditional methods of information dissemination (Usual Care or UC) for adoption of CER on prevention and management of diabetes, leading to better self-efficacy and clinical outcomes. The investigators will conduct a 12-month randomized controlled trial in older veterans with prediabetes and diabetes participating in one of the Healthy Aging Regional Collaborative programs. Primary outcomes include changes in self-efficacy, weight, and hemoglobin A1c. Secondary outcomes include changes in blood pressure, lipids, physical function, quality of life, and health care utilization and the evaluation of potential racial/ethnic disparities in the process of adoption of CER for prevention and management of diabetes. This study is expected to accelerate the implementation of CER evidence for diabetes prevention, addressing health and economic challenges in the care of overweight and obese veterans.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to prevention

What are the top hospitals conducting prevention research?

When it comes to groundbreaking clinical trials in the field of prevention, several top hospitals across the United States are making notable strides. Brigham and Women's Hospital in Boston leads the way with six active prevention trials aimed at identifying strategies to ward off various diseases. While they have yet to conduct any prevention trials historically, their commitment to preventive medicine is evident. Similarly, Mayo Clinic in Rochester is actively engaged in four ongoing prevention studies, focusing on innovative approaches to disease prevention. Although they also do not have a past record of conducting preventive trials, their dedication towards exploring preventative measures is commendable.

In Aurora, Colorado, Children's Hospital Colorado recognizes the importance of early intervention and has three active prevention trials underway. These efforts aim to identify ways to prevent or mitigate health issues from an early age and support children's well-being as they grow up.

Meanwhile, Dent Neurologic Institute located in Amherst acknowledges that preventing neurological disorders carries immense significance for overall health outcomes. They currently contribute by running three active clinical trials focused on preventive strategies within this realm.

Lastly,nestled away in Bellevue,the Northwest Clinical Research Center signifies its role as a crucial player by hosting three ongoing preventive clinical investigations without prior historical input.Their current endeavors involve pioneering research into preventative measures against various conditions related issues emphasizing their contribution towards ensuring healthier lives

These esteemed institutions demonstrate unwavering commitment toward mitigating risks before diseases surface and promoting overall wellness through proactive approaches.Across different locations these top-tier hospitals exemplify how ongoing collaborative work continues driving us closer than ever before towards cultivating healthier lives for everyone

Which are the best cities for prevention clinical trials?

When it comes to prevention clinical trials, several cities have emerged as leaders in research and development. Boston, Massachusetts leads the way with 18 active trials focusing on interventions like Enteric Coated Aspirin, Deferoxamine, and Vitamin d. New york, New York follows closely behind with 13 ongoing studies examining strategies such as targeted screening advice based on comprehensive risk assessments. Miami, Florida; Phoenix, Arizona; and Baltimore Maryland also contribute significantly to prevention research with their own set of active trials exploring various preventive measures. These cities offer individuals opportunities to participate in cutting-edge clinical trials aimed at preventing diseases and improving overall health outcomes.

Which are the top treatments for prevention being explored in clinical trials?

When it comes to prevention, clinical trials are currently investigating the efficacy of several promising treatments. The top contenders in these trials include:

  • Daratumumab: Being tested in multiple ongoing trials
  • Belantamab mafodotin: Showing potential as a preventive treatment
  • Lenalidomide: Under investigation for its preventive properties

These treatments hold promise for preventing breast cancer and may provide a breakthrough in the fight against this disease. Continued research and development are crucial to improving prevention strategies and ultimately reducing the burden of breast cancer worldwide.

What are the most recent clinical trials for prevention?

Exciting advancements are being made in the realm of prevention, as recent clinical trials offer promising approaches to safeguard against various health conditions. Among these studies is a Phase 2 trial investigating the efficacy of high-dose ORC-13661 for prevention. Additionally, a Phase 3 trial called ReMMiD-C Therapeutic Arm A aims to explore preventive strategies further. Another Phase 3 trial named ROSE (Reach Out, Stay Strong, Essentials) focuses on preventing complications in mothers with newborns. Furthermore, a Phase 2 trial examines the potential benefits of smartphones in preventive measures. Lastly, Stellate ganglion block is being explored through both Phase 2 and Phase 3 trials for its preventative properties. With these innovative initiatives underway, we can anticipate significant progress in disease prevention efforts moving forward.

What prevention clinical trials were recently completed?

Recently, several clinical trials focused on prevention have concluded, providing valuable insights into strategies for disease avoidance. These studies demonstrate the commitment of researchers to proactively addressing health concerns.